Department of Anaesthesia, Hamlet Hospital, Frederiksberg, Denmark.
Acta Anaesthesiol Scand. 2012 Mar;56(3):357-64. doi: 10.1111/j.1399-6576.2011.02621.x. Epub 2012 Jan 4.
Total knee arthroplasty (TKA) is associated with intense post-operative pain. Besides providing optimal analgesia, reduction in side effects and enhanced mobilization are important in this elderly population. The adductor-canal-blockade is theoretically an almost pure sensory blockade. We hypothesized that the adductor-canal-blockade may reduce morphine consumption (primary endpoint), improve pain relief, enhance early ambulation ability, and reduce side effects (secondary endpoints) after TKA compared with placebo.
Patients aged 50-85 years scheduled for TKA were included in this parallel double-blind, placebo-controlled randomized trial. The patients were allocated to receive a continuous adductor-canal-blockade with intermittent boluses via a catheter with either ropivacaine 0.75% (n = 34) or placebo (n = 37) (http://www.clinicaltrials.gov Identifier: NCT01104883).
Seventy-five patients were randomized in a 1 : 1 ratio and 71 patients were analyzed. Morphine consumption from 0 to 24 h was significantly reduced in the ropivacaine group compared with the placebo group (40 ± 21 vs. 56 ± 26 mg, P = 0.006). Pain was significantly reduced in the ropivacaine group during 45 degrees flexion of the knee (P = 0.01), but not at rest (P = 0.06). Patients in the ropivacaine group performed the ambulation test, the Timed-Up-and-Go (TUG) test, at 24 h significantly faster than patients in the placebo group (36 ± 17 vs. 50 ± 29 s, P = 0.03).
The adductor-canal-blockade significantly reduced morphine consumption and pain during 45 degrees flexion of the knee compared with placebo. In addition, the adductor-canal-blockade significantly enhanced ambulation ability assessed by the TUG test.
全膝关节置换术(TKA)术后疼痛剧烈。除了提供最佳的镇痛效果外,减少副作用和增强活动能力对于老年患者也很重要。收肌管阻滞在理论上是一种几乎纯粹的感觉阻滞。我们假设与安慰剂相比,收肌管阻滞可能会减少吗啡的消耗(主要终点),改善疼痛缓解,增强早期活动能力,并减少 TKA 后的副作用(次要终点)。
本研究纳入了计划接受 TKA 的 50-85 岁患者,进行了一项平行、双盲、安慰剂对照的随机临床试验。将患者分为两组,分别接受罗哌卡因 0.75%(n=34)或安慰剂(n=37)的连续收肌管阻滞,同时通过导管间歇性推注(http://www.clinicaltrials.gov 标识符:NCT01104883)。
75 名患者按 1:1 比例随机分组,71 名患者纳入分析。与安慰剂组相比,罗哌卡因组 0-24 小时的吗啡消耗量显著减少(40±21 vs. 56±26mg,P=0.006)。罗哌卡因组在膝关节 45 度屈曲时疼痛明显减轻(P=0.01),但在休息时无差异(P=0.06)。与安慰剂组相比,罗哌卡因组患者在 24 小时时的步行测试(TUG)测试中,行走时间显著更快(36±17 vs. 50±29s,P=0.03)。
与安慰剂相比,收肌管阻滞可显著减少吗啡消耗和膝关节 45 度屈曲时的疼痛。此外,收肌管阻滞还显著增强了 TUG 测试评估的活动能力。